Addex regains rights to preclinical asset from Merck & Co

Addex Pharmaceuticals Ltd has taken back rights to a preclinical asset that had been licensed to Merck & Co for schizophrenia. At the same time, it is progressing a second partnership with Merck for a candidate drug for Parkinson’s disease.